NCT00507182 is a NA clinical trial of Fluorescence Spectroscopy in Oral Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT00507182?

NCT00507182 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT00507182?

Interventions in NCT00507182: Fluorescence Spectroscopy.

What condition does NCT00507182 study?

NCT00507182 studies Oral Cancer.

Is NCT00507182 still recruiting?

NCT00507182 is currently completed. Last updated 19 January 2018.

Last reviewed 2018-01-19 · How we verify

NCT00507182

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions

Completed NA Last updated 19 January 2018

What this trial tests

NA trial testing Fluorescence Spectroscopy in Oral Cancer in 381 participants. Completed in 12 January 2018.

Timeline

2 July 1999

Primary endpoint
12 January 2018

12 January 2018

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	381
Start date	2 July 1999
Primary completion	12 January 2018
Estimated completion	12 January 2018
Sites	1 location across United States

Drugs / interventions tested

Fluorescence Spectroscopy

Conditions studied

Oral Cancer — all drugs for Oral Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Oral Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to test a new way to look for cancer and pre-cancerous tissue changes inside the mouth.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Fluorescence Spectroscopy

Trials testing the same drug.

NCT00542373 — Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for De · NA · active not recruiting

Other recruiting trials for Oral Cancer

Currently open trials in the same condition.

NCT07509619 — AI-based Physiotherapy Evaluation System for Range of Motion in Oral Cancer Patients · recruiting
NCT07260344 — Evaluation of Two Non-Invasive Methods, High-Resolution Microendoscopy and Liquid-Based Cytology, for Detection of Oral · NA · recruiting
NCT06682494 — Enhancing Oral Cancer Awareness · NA · recruiting
NCT07095608 — Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain · NA · recruiting
NCT07296250 — Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT · NA · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00507182 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 19 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00507182.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing